Ronald Barbaras
Balma, 31130, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project.
Journal: BMC medicine
Published: April 06, 2023
CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency.
Journal: Metabolism: clinical and experimental
Published: October 15, 2020
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.
Journal: Clinical drug investigation
Published: February 19, 2017
HDL mimetic CER-001 targets atherosclerotic plaques in patients.
Journal: Atherosclerosis
Published: March 24, 2016
HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.
Journal: PloS one
Published: March 18, 2015
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.
Journal: Journal of lipid research
Published: January 07, 2015
P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo.
Journal: PloS one
Published: January 22, 2014
CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Journal: Atherosclerosis
Published: July 02, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026